carcinoma of unknown primary ihc approach
TRANSCRIPT
![Page 1: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/1.jpg)
Carcinomas of Unknown Primary Site Kandalaft et al
(Arch Pathol Lab Med.doi: 10.5858/arpa.2015-0173-CP)
PRACTICAL APPLICATIONS IN
IMMUNOHISTOCHEMISTRY
![Page 2: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/2.jpg)
Approximately 4% of all patients with cancer present as CUPs
IHC remains a gold standard at diagnosis
2 classes of antibody markers that can help- Antibodies to keratins- Antibodies to organ restricted markers
![Page 3: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/3.jpg)
Determine the cell line of differentiation
Determine the CK type or types of distribution
Determine co expression of vimentin
Determine expression of supplemental Ags (CEA, EMA, PLAP)
Organ specific markers
![Page 4: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/4.jpg)
KERATINSLow molecular
weight CK- “simple” epithelium- K8, K18- Glandular epithelium
of GIT, hepatocytes
High molecular weight CK
- “complex” epithelium
- K5, K14, K17- Stratified epithelium- Ductal and basal
cellsThe subclassification of carcinomas by HMW and LMW keratins has largely been superseded by subclassification using antibodies to K7 and K20 which is a far more powerful discriminator
![Page 5: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/5.jpg)
CK 7 AND CK 20 - APPROACH
Cancer of Unknown PrimaryMD Anderson Cancer Center
![Page 6: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/6.jpg)
Urothelial tumorsOvarian mucinous adenocarcinomaPancreatic adenocarcinomaCholangiocarcinomaGastric carcinoma
CK 7 POSITIVE/CK 20 POSITIVE
![Page 7: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/7.jpg)
Lung adenocarcinomaBreast carcinomaThyroid carcinomaSalivary gland carcinomaEsophageal carcinoma
Endometrial carcinomaCervical carcinoma
CholangiocarcinomaPancreatic carcinomaGastric carcinoma
CK 7 POSITIVE/CK 20 NEGATIVE
As a rule, gastric
adenocarcinoma can show almost any
K7/K20 phenotype
![Page 8: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/8.jpg)
Colorectal carcinomaMerkel cell carcinoma (dot like pattern)
CK 7 NEGATIVE/CK 20 POSITIVE
![Page 9: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/9.jpg)
Hepatocellular carcinomaRenal cell carcinomaProstate carcinomaSquamous cell and small cell lung carcinomaHead and neck carcinoma
CK 7 NEGATIVE/CK 20 NEGATIVE
![Page 10: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/10.jpg)
Keratin 5 (and its pair 14) – marker of squamous, transitional cell, myoepithelial and mesothelial differentiation
Keratin 17 – when expressed at high levels good marker for distinguishing between carcinomas of pancreatobiliary origin from gastric carcinomas
OTHER KERATINS
![Page 11: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/11.jpg)
CK AND VIMENTIN COEXPRESSIONCARCINOMAS
Anaplastic thyroid carcinoma
Endometrial carcinomaMesotheliomaMetaplastic breast
carcinomaMyoepithelial carcinomaRenal cell carcinomaSarcomatoid carcinomaThyroid carcinomas
MESENCHYMALAdamantinomaChordomaDPSRCTEpithelioid
angiosarcomaEpithelioid sarcomaLeiomyosarcomaMalignant rhabdoid
tumorSynovial sarcoma
![Page 12: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/12.jpg)
ORGAN SPECIFIC MARKERS
![Page 13: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/13.jpg)
CLASSES OF TUMOR SPECIFIC ANTIBODIES
CYTOPLASMIC- Level of expression
and fraction Function of the state of differentiation of the tumor
NUCLEAR- When positive
entire tumor population
- Independent of the state of differentiation
![Page 14: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/14.jpg)
BREAST CANCER MARKERS
![Page 15: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/15.jpg)
2/3rd to 3/4th of primary breast Lower fraction of breast cancer in metastatic
sites
Primary in endometrium and ovaryPapillary carcinoma thyroidSkin adnexal tumors
10-20% of lung adenocarcinomas (focally)
Rare in adenocarcinoms of GIT
ESTROGEN RECEPTOR
![Page 16: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/16.jpg)
23A3 monoclonal antibody- 80% sensitivityFunction of histological subtypeGreatest in lobular (particularly those with
signet ring cells) and those with apocrine features
Very small fraction of basal like carcinomas
Salivary gland carcinomas and sweat gland carcinomas
5-10% primary ovarian and endometrial carcinomas
5-6% lung adenocarcinomas
GCDFP 15
![Page 17: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/17.jpg)
Sensitivity as a marker of breast cancer is LESS than that of GCDFP 15 (50-70%)
7% breast cancers are Mammaglobin A positive but GCDFP 15 negative
10% of ovarian and endometrial Skin adnexal and salivary gland tumors
MAMMAGLOBIN A
![Page 18: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/18.jpg)
1 of 6 members of zinc finger transcription factor family
Very sensitive for breast and urothelial carcinoma
Ductal 91%, lobular 100% diffuse and strong nuclear staining
UNLIKE previous two seen in 43% of triple negative and 54% of metaplastic breast cancers
Maintained in metastatic breast cancer (>90%)
Skin adnexal, endometrial, pancreatic, salivary gland carcinomas
GATA BINDING PROTEIN 3
![Page 19: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/19.jpg)
LUNG CANCER MARKERS
![Page 20: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/20.jpg)
NKX2 family of DNA binding transcription factors
Selectively expressed during embryogenesis in the thyroid, diencephalon and respiratory epithelium
Expressed in both neuroendocrine and non neuroendocrine tumors of the lung
THYROID TRANSCRIPTION FACTOR-1
![Page 21: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/21.jpg)
Sensitivity of TTF-1 is greatest among adenocarcinomas and nonmucinous bronchioloalveolar carcinomas
Lowest in mucinous adenocarcinomas and squamous cell carcinomas
Appears to retain similar sensitivity in metastatic sites
Small subset of ovarian, endometrial, and colorectal carcinomas, although the extent of positivity is usually focal, often in isolated clusters of cells
![Page 22: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/22.jpg)
TTF-1 expression cannot be considered specific for high-grade neuroendocrine carcinomas of lung origin
Variable subset of small cell (neuroendocrine) carcinomas of the genitourinary and gynecologic (GYN) tract
Cell blocks of pleural fluids, which contain material that has been either fixed in alcohol or is nonfixed before creation of a formalin-fixed cell pellet, can manifest a profound loss of TTF-1 antigenicity
![Page 23: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/23.jpg)
Aspartic protease that is crucial to the maturation of surfactant B and present in the cytoplasm of type 2 pneumocytes and alveolar macrophages
Very sensitive marker for detecting pulmonary adenocarcinomas
Subset of renal cell carcinomasMinority of endometrial adenocarcinomas and
papillary thyroid carcinomasVirtually all cases of clear cell carcinomas of the
ovary
NAPSIN A
![Page 24: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/24.jpg)
GI TRACT MARKERS
![Page 25: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/25.jpg)
Nuclear transcription factor controlling the proliferation and differentiation of intestinal epithelial cells
Virtually 100% of colorectal adenocarcinomas
MSI reduced or even absent expression
CRC uniform staining patternMost adenocarcinomas of the stomach,
pancreas, and biliary tract variegated or focal staining pattern
CDX2
![Page 26: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/26.jpg)
½ gastric (more in intestinal type) and 1/3 of pancreatobiliary
Ovarian mucinous carcinomas, bladder adenocarcinomas, and sinonasal intestinal type adenocarcinomas
Limited subset of mucinous and nonmucinous pulmonary adenocarcinomas (enteric subtype)
![Page 27: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/27.jpg)
Endocervical and endometrial mucinous differentiation
‘‘Squamous’’ morules of endometrioid hyperplasia and carcinoma
Germ cell tumors intestinal differentiation
GI neuroendocrine tumors, including those primary to the intestine (eg, carcinoid tumors) and, to a variable degree, the pancreas (islet cell tumors)
![Page 28: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/28.jpg)
Actin-binding protein, found preferentially in microvilli
Expression is largely (but not entirely) restricted to glandular epithelium and corresponding adenocarcinomas of the GI tract
Expression is greatest and most reliably found in CRC
Lower levels of expression are found in adenocarcinomas primary to the pancreatobiliary tract and stomach
VILLIN
![Page 29: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/29.jpg)
Scoring of the membranous or ‘‘brush border’’ signal is most significant
Cytoplasmic immunostaining can be seen in other types of tumors, particularly neuroendocrine carcinomas
Can also be seen in adenocarcinomas of other sites that display a GI-type histology and immunophenotype
Although the individual sensitivities of CDX2 and villin are each approximately 50%, their combined sensitivity is in excess of 75%.
![Page 30: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/30.jpg)
HEPATOCELLULAR MARKERS
![Page 31: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/31.jpg)
Detects a liver (hepatocyte)-specific marker, subsequently found to represent the enzyme carbamoyl phosphate synthase
Helps to distinguish metastatic carcinomas from primary HCCs
(1%–10%) subset of adenocarcinomas primary to the lung, pancreas, stomach, ovaries, and adrenal cortex hepatoid morphology
HEP-PAR 1 ANTIBODY (CPS1)
![Page 32: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/32.jpg)
Enzyme involved in the urea cycle
Appears to represent the most-sensitive (and, perhaps, most-specific) marker of HCC to date
Cytoplasmic, granular pattern
High level of sensitivity even in the context of high-grade HCC
ARGINASE-1
![Page 33: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/33.jpg)
It is not expressed in ‘‘hepatoid’’ and other non-HCCs (particularly carcinomas of the lung, stomach, and kidney)
This is the marker of choice for identifying HCC
![Page 34: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/34.jpg)
Oncofetal protein
Proven useful in distinguishing HCC from nonneoplastic hepatic lesions and hepatic adenomas
In mets vs primary high level of sensitivity and specificity of arginase-1 to surpass the use of glypcian-3
GLYPICAN 3
![Page 35: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/35.jpg)
GYN CANCER MARKERS
![Page 36: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/36.jpg)
Nuclear transcription factor implicated in tumorigenesis and in specifying normal urogenital development
Mesothelial cells, ovarian surface epithelium, mesangial cells in the kidney, a subset of smooth muscle cells, and granulocytic cells and precursors
WILMS TUMOR ANTIBODY (WT1)
![Page 37: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/37.jpg)
Marker of ovarian carcinomas in the context of adenocarcinomas
Mesothelioma distinguishing it from nonovarian adenocarcinomas
Desmoplastic small, round cell tumors
Ovarian serous carcinomas, primary peritoneal adenocarcinomas, and fallopian tube serous carcinomas
Very high sensitivity and specificity, both in excess of 90%.
![Page 38: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/38.jpg)
In a poorly differentiated ovarian carcinoma, nuclear WT1 reactivity favors a serous neoplasm because endometrioid, clear cell and mucinous carcinomas are negative
In the breast, WT1 is expressed in around 6% of the cases, usually at low levels in pure mucinous (65%) and mixed mucinous (33%) subtypes
![Page 39: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/39.jpg)
Subset of carcinomas arising within the female genital tract, exhibit nuclear expression for ER
In endometrial carcinomas of endometrioid type (type 1), ER antibodies are reactive
Whereas in uterine serous and clear cell carcinomas (type 2), they usually are not
ESTROGEN RECEPTOR
![Page 40: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/40.jpg)
Can be part of a panel to differentiate endometrial adenocarcinoma from endocervical adenocarcinoma
No value in the distinction between a primary ovarian adenocarcinoma (mainly including endometrioid and serous carcinoma) and a metastasis from the breast or from elsewhere within the female genital tract
![Page 41: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/41.jpg)
Transcription factor, which is critical to embryogenesis of the thyroid gland, kidney, and mullerian system
Nonciliated, mucosal cells of the fallopian tubes, endocervix, endometrium, and simple ovarian inclusion cysts BUT NOT on the surface of the epithelial cells of the ovary
90% to 100% of serous, endometrioid, clear cell, and transitional cell ovarian carcinomas
PAX 8
![Page 42: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/42.jpg)
PAX8 is not expressed in mammary carcinomas, including ductal and lobular types
Because the ovary is a common site of involvement for metastasis by breast carcinoma, PAX8 can be a useful marker in the differential diagnosis of ovarian and breast carcinomas
![Page 43: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/43.jpg)
Highly expressed in clear cell carcinomas of the ovary 100% of tumors
Clear cell carcinomas of the endometrium (82%)
Few endometrial serous carcinomas (8%)
NO endometrioid endometrial carcinoma
NAPSIN A
![Page 44: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/44.jpg)
PROSTATE MARKERS
![Page 45: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/45.jpg)
Very high sensitivity of this marker, apparently independent of Gleason score
Overall sensitivity in the range of 95% and specificity approaching 100%
Expressed by a subset of breast cancers
Also expressed focally in salivary gland and pancreatic carcinomas
PROSTATE SPECIFIC ANTIGEN
![Page 46: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/46.jpg)
Antibody to the prostatic tumor suppressor gene NKX3.1
Recently reported to be an extremely sensitive marker for identifying metastatic prostatic adenocarcinoma (positive in 99%)
Level of sensitivity of NKX3.1 is maintained in high-grade prostatic carcinomas
NKX3.1
![Page 47: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/47.jpg)
TCC MARKERS
![Page 48: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/48.jpg)
More than 90% of urothelial carcinomas are positive
Useful marker in distinguishing TCC from other non–small cell carcinomas potentially in the differential diagnosis, such as, prostatic adenocarcinoma (especially high grade)
GATA3
![Page 49: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/49.jpg)
Glycoprotein of the asymmetrical unit membrane, which forms plaques on the apical surfaces of urothelial umbrella cells
First, specific, urothelial-restricted marker described
High sensitivity in non invasive; low sensitivity in invasive
UROPLAKIN
![Page 50: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/50.jpg)
RENAL CELL CARCINOMA MARKERS
![Page 51: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/51.jpg)
Critical to the embryogenesis of the kidney, is identified in renal tubular epithelium and vas deferens, but not glomeruli
Most of the renal epithelial neoplasms
Clear cell > Papillary > Chromophobe = Sarcomatoid = Xp11 Translocation
Not expressed in bladder TCCSubset of renal pelvic urothelial carcinomas
PAX8
![Page 52: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/52.jpg)
THYROID MARKERS
![Page 53: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/53.jpg)
Specific and sensitive markers of both primary and metastatic carcinomas of the thyroid
Excellent marker of papillary and follicular carcinomas
Poor marker of anaplastic
NOT a marker for medullary
THYROGLOBULIN
![Page 54: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/54.jpg)
Even more-sensitive marker of thyroid carcinomas than thyroglobulin
Medullary also
Anaplastic negative
TTF 1
![Page 55: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/55.jpg)
Critical to the organogenesis of the thyroid gland and is highly expressed in the thyroid follicular epithelium
Papillary and follicular 100%
Anaplastic 80%
PAX8 is useful in discriminating between a TTF-1 + lung adenocarcinoma and a TTF-1+ thyroid carcinoma because PAX8 expression has not been identified in primary lung adenocarcinomas
PAX8
![Page 56: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/56.jpg)
ADRENAL MARKERS
![Page 57: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/57.jpg)
Expressed in a restricted subset of healthy cells, including ovarian granulosa cells, testicular Leydig cells, and adrenal cortical epithelium
Excellent marker for the identification of primary adrenal cortical tumors and their distinction from metastatic carcinomas to the adrenal gland
Ovarian and testicular stromal tumors
INHIBIN α
![Page 58: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/58.jpg)
Alternative or supplementary marker of adrenal cortical differentiation
Sensitivity is comparable or even greater than that of Inhibin
MART 1 ANTIGEN
![Page 59: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/59.jpg)
100% specificity at discriminating these neoplasms from other tumors with clear cell morphology, such as renal cell carcinoma, ovarian clear cell carcinoma, and chordomas
High levels in sex cord-stromal tumors of the ovary
Lower levels in testicular sex cord-stromal tumors
STEROIDOGENIC FACTOR 1
![Page 60: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/60.jpg)
Unique among epithelial tumors very low level of keratins
Unique among nonneuroendocrine tumors synaptophysin
ANOMALOUS FINDINGS IN ADRENAL CORTICAL TUMORS
![Page 61: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/61.jpg)
SQUAMOUS/ TRANSITIONAL CELL MARKERS (p63 and p40)
![Page 62: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/62.jpg)
Uniformly and strongly p63 and p40 positive pure SCC (lung and cervix)
Thymomas can also be positive
SQUAMOUS DIFFERENTIATION
![Page 63: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/63.jpg)
Uniform expression of p63 and p40, even in the setting of poorly differentiated tumors, such as spindle cell, bladder TCC
TRANSITIONAL DIFFERENTIATION
![Page 64: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/64.jpg)
Carcinomas demonstrating myoepithelial differentiation (eg, adenoid cystic and other salivary gland carcinomas)
Carcinomas demonstrating trophoblastic differentiation.
NONSQUAMOUS, NONTRANSITIONAL CARCINOMAS
![Page 65: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/65.jpg)
CASE 1
![Page 66: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/66.jpg)
73 years old man
Long term smoker
Needle biopsy of single left lower lobe lung nodule
![Page 67: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/67.jpg)
CK 20
CDX 2 TTF 1
![Page 68: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/68.jpg)
Diagnosis Metastatic adenocarcinoma from rectosigmoid
![Page 69: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/69.jpg)
CASE 2
![Page 70: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/70.jpg)
63 years old male
Cervical lymph node needle biopsy
No known primary
Suspicious for lymphoma
![Page 71: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/71.jpg)
CK 7
PSA VILLIN
![Page 72: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/72.jpg)
Diagnosis Metastatic prostatic adenocarcinoma
![Page 73: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/73.jpg)
CASE 3
![Page 74: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/74.jpg)
55 years old woman
Right axillary lymph node biopsy
Ill defined density seen on mammogram
PET positive uptake in right parotid gland
![Page 75: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/75.jpg)
GCDFP-15
GATA 3 HER 2
![Page 76: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/76.jpg)
Diagnosis Metastatic ductal carcinoma from breast
![Page 77: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/77.jpg)
CASE 4
![Page 78: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/78.jpg)
73 years old woman
Needle biopsy of retroperitoneal lymph node
History of hysterectomy for unknown reasons many years back
Retroperitoneal lymphadenopathy, possible splenic metastasis
Left pelvic sidewall mass on CT scan - ?residual ovary
![Page 79: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/79.jpg)
ER
WT 1 PAX8
![Page 80: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/80.jpg)
Diagnosis Metastatic high grade serous carcinoma of ovary
![Page 81: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/81.jpg)
CASE 5
![Page 82: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/82.jpg)
58 years old man
Needle biopsy of mediastinal lymph node
Recent diagnosis of prostate adenocarcinoma (Gleason score 4, “hypernephroid”)
Nephrectomy 5 years ago for sarcomatoid renal cell carcinoma
Remote history of melanoma
Presented with mediastinal and lung masses
![Page 83: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/83.jpg)
CK
PSA
PAX 8
![Page 84: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/84.jpg)
Diagnosis PAX 8 + male thyroid and renal TTF negativeMetastatic renal cell carcinoma
![Page 85: Carcinoma of unknown primary IHC Approach](https://reader036.vdocuments.net/reader036/viewer/2022070600/589eecc91a28abe97f8b5d77/html5/thumbnails/85.jpg)
Thank You